Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
04 2019
Historique:
received: 30 10 2017
revised: 18 12 2017
accepted: 21 12 2017
pubmed: 20 2 2018
medline: 14 1 2020
entrez: 19 2 2018
Statut: ppublish

Résumé

The purpose of this study was to investigate the association between right ventricular dysfunction (RVD) and cardiovascular death after transcatheter aortic valve replacement (TAVR). There is conflicting evidence on the effect of RVD on clinical outcomes after TAVR. A total of 1,116 TAVR patients (age 82 ± 6 years; 51% female) who were consecutively enrolled into a prospective registry underwent detailed pre-operative assessment of right ventricular (RV) function and were dichotomized into 2 groups for the purposes of the present retrospective analysis. RVD was assessed using fractional area change (<35%), tricuspid annular plane systolic excursion (<1.7 cm), and systolic movement of the RV lateral wall by tissue Doppler imaging (<9.5 cm/s). RVD was found in 325 (29.1%) patients. The primary outcome was cardiovascular death at 1 year. After adjustment for comorbidities, patients with RVD had a higher risk of cardiovascular death at 1 year compared with patients with normal RV function (20.1% vs. 7.1%; adjusted hazard ratio [HR RVD at baseline was associated with a more than 2-fold increased risk of cardiovascular death at 1 year after TAVR, with a gradient of risk according to RVD recovery. (Swiss TAVI Registry; NCT01368250).

Sections du résumé

OBJECTIVES
The purpose of this study was to investigate the association between right ventricular dysfunction (RVD) and cardiovascular death after transcatheter aortic valve replacement (TAVR).
BACKGROUND
There is conflicting evidence on the effect of RVD on clinical outcomes after TAVR.
METHODS
A total of 1,116 TAVR patients (age 82 ± 6 years; 51% female) who were consecutively enrolled into a prospective registry underwent detailed pre-operative assessment of right ventricular (RV) function and were dichotomized into 2 groups for the purposes of the present retrospective analysis. RVD was assessed using fractional area change (<35%), tricuspid annular plane systolic excursion (<1.7 cm), and systolic movement of the RV lateral wall by tissue Doppler imaging (<9.5 cm/s). RVD was found in 325 (29.1%) patients. The primary outcome was cardiovascular death at 1 year.
RESULTS
After adjustment for comorbidities, patients with RVD had a higher risk of cardiovascular death at 1 year compared with patients with normal RV function (20.1% vs. 7.1%; adjusted hazard ratio [HR
CONCLUSIONS
RVD at baseline was associated with a more than 2-fold increased risk of cardiovascular death at 1 year after TAVR, with a gradient of risk according to RVD recovery. (Swiss TAVI Registry; NCT01368250).

Identifiants

pubmed: 29454762
pii: S1936-878X(18)30012-3
doi: 10.1016/j.jcmg.2017.12.015
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT01368250']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

577-587

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Masahiko Asami (M)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Stefan Stortecky (S)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Fabien Praz (F)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Jonas Lanz (J)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Lorenz Räber (L)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Anna Franzone (A)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Raffaele Piccolo (R)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

George C M Siontis (GCM)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Dik Heg (D)

Institute of Social and Preventive Medicine and Clinical Trials Unit, University of Bern, Bern, Switzerland.

Marco Valgimigli (M)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Peter Wenaweser (P)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Eva Roost (E)

Department of Cardiac Surgery, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Stephan Windecker (S)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.

Thomas Pilgrim (T)

Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland. Electronic address: thomas.pilgrim@insel.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH